Abstract
Tumor cells often evade killing by the complement system by overexpressing membrane-bound complement inhibitors. However, production of soluble complement inhibitors in cells other than hepatocytes was rarely reported. We screened several breast cancer cell lines for expression of soluble complement inhibitor, complement factor I (FI). We also analyzed local production of FI in tissue microarrays with tumors from 130 breast cancer patients by in situ hybridization and immunohistochemistry. We found expression of FI in breast adenocarcinoma cell line MDA-MB-468 and confirmed its functional activity. Expression of FI at mRNA and protein levels was also confirmed in tumor cells and tumor stroma, both in fibroblasts and infiltrating immune cells. Multivariate Cox regression analyses revealed that high expression of FI protein in tumor cells was correlated with significantly shorter cancer-specific survival (HR 2.8; 95 % CI 1.0–7.5; p = 0.048) and recurrence-free survival (HR 3.4; 95 % CI 1.5–7.4; p = 0.002). High FI expression was positively correlated with tumor size (p < 0.001), and Nottingham histological grade (p = 0.015) and associated with estrogen and progesterone receptor status (p = 0.03 and p = 0.009, respectively). Our data show that FI is expressed in breast cancer and is associated with unfavorable clinical outcome.
Similar content being viewed by others
Abbreviations
- ATCC:
-
American Type Culture Collection
- CDCC:
-
Complement-dependent cell cytotoxicity
- CI:
-
Confidence interval
- CSS:
-
Cancer-specific survival
- C4BP:
-
C4b-binding protein
- ER:
-
Estrogen receptor
- FH:
-
Complement factor H
- FI:
-
Complement factor I
- Her2:
-
Epidermal growth factor receptor 2
- HR:
-
Hazard ratio
- MOPS:
-
3-(N-morpholino)propanesulfonic acid
- NHG:
-
Nottingham histological grade
- NSCLC:
-
Non-small cell lung cancer
- PR:
-
Progesterone receptor
- PVDF:
-
Polyvinylidene difluoride
- RFS:
-
Recurrence-free survival
- SDS–PAGE:
-
Sodium dodecyl sulfate, polyacrylamide gel electrophoresis
- TMA:
-
Tissue microarray
References
Ricklin D, Hajishengallis G, Yang K, Lambris JD (2010) Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11:785–797. doi:10.1038/ni.1923
Okroj M, Osterborg A, Blom AM (2013) Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies. Cancer Treat Rev 39:632–639. doi:10.1016/j.ctrv.2012.10.008
Jurianz K, Ziegler S, Garcia-Schuler H, Kraus S, Bohana-Kashtan O, Fishelson Z, Kirschfink M (1999) Complement resistance of tumor cells: basal and induced mechanisms. Mol Immunol 36:929–939
Mark L, Lee WH, Spiller OB, Proctor D, Blackbourn DJ, Villoutreix BO, Blom AM (2004) The Kaposi’s sarcoma-associated herpesvirus complement control protein mimics human molecular mechanisms for inhibition of the complement system. J Biol Chem 279:45093–45101
Ajona D, Hsu YF, Corrales L, Montuenga LM, Pio R (2007) Down-regulation of human complement factor H sensitizes non-small cell lung cancer cells to complement attack and reduces in vivo tumor growth. J Immunol 178:5991–5998
Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C, Coukos G, Lambris JD (2008) Modulation of the antitumor immune response by complement. Nat Immunol 9:1225–1235. doi:10.1038/ni.1655
Corrales L, Ajona D, Rafail S, Lasarte JJ, Riezu-Boj JI, Lambris JD, Rouzaut A, Pajares MJ, Montuenga LM, Pio R (2012) Anaphylatoxin c5a creates a favorable microenvironment for lung cancer progression. J Immunol 189:4674–4683. doi:10.4049/jimmunol.1201654
Schlaf G, Demberg T, Beisel N, Schieferdecker HL, Gotze O (2001) Expression and regulation of complement factors H and I in rat and human cells: some critical notes. Mol Immunol 38:231–239
Holers VM (2014) Complement and its receptors: new insights into human disease. Ann Rev Immunol 32:433–459. doi:10.1146/annurev-immunol-032713-120154
Stover C (2010) Dual role of complement in tumour growth and metastasis (review). Int J Mol Med 25:307–313
Minta JO, Fung M, Paramaswara B (1998) Transcriptional and post-transcriptional regulation of complement factor I (CFI) gene expression in Hep G2 cells by interleukin-6. Biochim Biophys Acta 1442:286–295
Vetvicka V, Reed W, Hoover ML, Ross GD (1993) Complement factors H and I synthesized by B cell lines function to generate a growth factor activity from C3. J Immunol 150:4052–4060
Gasque P, Julen N, Ischenko AM, Picot C, Mauger C, Chauzy C, Ripoche J, Fontaine M (1992) Expression of complement components of the alternative pathway by glioma cell lines. J Immunol 149:1381–1387
Legoedec J, Gasque P, Jeanne JF, Fontaine M (1995) Expression of the complement alternative pathway by human myoblasts in vitro: biosynthesis of C3, factor B, factor H and factor I. Eur J Immunol 25:3460–3466. doi:10.1002/eji.1830251238
Okroj M, Hsu YF, Ajona D, Pio R, Blom AM (2008) Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors. Mol Immunol 45:169–179
Riihila P, Nissinen L, Farshchian M, Kivisaari A, Ala-Aho R, Kallajoki M, Grenman R, Meri S, Peltonen S, Peltonen J, Kahari VM (2015) Complement factor I promotes progression of cutaneous squamous cell carcinoma. J Invest Dermatol 135:579–588. doi:10.1038/jid.2014.376
Nilsson SC, Karpman D, Vaziri-Sani F, Kristoffersson AC, Salomon R, Provot F, Fremeaux-Bacchi V, Trouw LA, Blom AM (2007) A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation. Mol Immunol 44:1835–1844. doi:10.1016/j.molimm.2006.10.005
Malm S, Jusko M, Eick S, Potempa J, Riesbeck K, Blom AM (2012) Acquisition of complement inhibitor serine protease factor I and its cofactors C4b-binding protein and factor H by Prevotella intermedia. PLoS ONE 7:e34852. doi:10.1371/journal.pone.0034852
Nilsson SC, Kalchishkova N, Trouw LA, Fremeaux-Bacchi V, Villoutreix BO, Blom AM (2010) Mutations in complement factor I as found in atypical hemolytic uremic syndrome lead to either altered secretion or altered function of factor I. Eur J Immunol 40:172–185. doi:10.1002/eji.200939280
Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3:RESEARCH0034
Nilsson SC, Blom AM (2014) Purification and functional characterization of factor I. Methods Mol Biol 1100:177–188. doi:10.1007/978-1-62703-724-2_15
Greenwood FC, Hunter WM, Glover JS (1963) The preparation of I-131-labelled human growth hormone of high specific radioactivity. Biochem J 89:114–123
Mohlin FC, Blom AM (2014) Purification and functional characterization of C4b-binding protein (C4BP). Methods Mol Biol 1100:169–176. doi:10.1007/978-1-62703-724-2_14
Helczynska K, Larsson AM, Mengelbier LH, Bridges E, Fredlund E, Borgquist S, Landberg G, Pahlman S, Jirstrom K (2008) Hypoxia-inducible factor-2alpha correlates to distant recurrence and poor outcome in invasive breast cancer. Cancer Res 68:9212–9220. doi:10.1158/0008-5472.CAN-08-1135
Svensson KJ, Christianson HC, Kucharzewska P, Fagerstrom V, Lundstedt L, Borgquist S, Jirstrom K, Belting M (2011) Chondroitin sulfate expression predicts poor outcome in breast cancer. Int J Oncol 39:1421–1428. doi:10.3892/ijo.2011.1164
Borgquist S, Holm C, Stendahl M, Anagnostaki L, Landberg G, Jirstrom K (2008) Oestrogen receptors alpha and beta show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer. J Clin Pathol 61:197–203. doi:10.1136/jcp.2006.040378
Ryden L, Jirstrom K, Bendahl PO, Ferno M, Nordenskjold B, Stal O, Thorstenson S, Jonsson PE, Landberg G (2005) Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer. J Clin Oncol 23:4695–4704. doi:10.1200/JCO.2005.08.126
Wang F, Flanagan J, Su N, Wang LC, Bui S, Nielson A, Wu X, Vo HT, Ma XJ, Luo Y (2012) RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn 14:22–29. doi:10.1016/j.jmoldx.2011.08.002
Blom AM, Kask L, Dahlbäck B (2003) CCP1-4 of the C4b-binding protein a-chain are required for factor I mediated cleavage of C3b. Mol Immunol 39:547–556
Cui T, Chen Y, Knösel T, Yang L, Zöller K, Galler K, Berndt A, Mihlan M, Zipfel PF, Petersen I (2011) Human complement factor H is a novel diagnostic marker for lung adenocarcinoma. Int J Oncol 39:161–168. doi:10.3892/ijo.2011.1010
Okroj M, Corrales L, Stokowska A, Pio R, Blom AM (2009) Hypoxia increases susceptibility of non-small cell lung cancer cells to complement attack. Cancer Immunol Immunother 58:1771–1880. doi:10.1007/s00262-009-0685-8
Ullman CG, Chamberlain D, Ansari A, Emery VC, Haris PI, Sim RB, Perkins SJ (1998) Human complement factor I: its expression by insect cells and its biochemical and structural characterisation. Mol Immunol 35:503–512
O’Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, Foulkes WD, Dressler LG, Geradts J, Millikan RC (2010) Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 16:6100–6110. doi:10.1158/1078-0432.CCR-10-1533
Munn LL (2003) Aberrant vascular architecture in tumors and its importance in drug-based therapies. Drug Discov Today 8:396–403
Ross GD, Vĕtvicka V (1993) CR3 (CD11b, CD18): a phagocyte and NK cell membrane receptor with multiple ligand specificities and functions. Clin Exp Immunol 92:181–184
Acknowledgments
We are grateful to Dr. Linda Werner-Hartman for help with statistical analyses, to Prof. Tommy Andersson for sharing breast cancer cell lines, Viktor Fransson for technical help with purification of FI antibodies and to Dr. Sara Nilsson for producing recombinant FI used for affinity purification of antibodies. This work was supported by the Swedish Cancer Society (to Anna Blom), the Swedish Research Council grants (K2012-66X-14928-09-5 to Anna Blom and K2010-80X-21514-01-4 to Marcin Okroj), grant for clinical research (ALF, to Anna Blom) and the Foundations of Österlund (to Anna Blom), Greta and Johan Kock (to Anna Blom), Malmo Cancer (to Marcin Okroj and Anna Blom), Tore Nilsson (to Marcin Okroj), Knut and Alice Wallenberg (to Anna Blom) and Inga-Britt and Arne Lundberg (to Anna Blom), as well as grants from the Skåne University Hospital (to Anna Blom and Marcin Okroj).
Conflict of interest
Authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Okroj, M., Holmquist, E., Nilsson, E. et al. Local expression of complement factor I in breast cancer cells correlates with poor survival and recurrence. Cancer Immunol Immunother 64, 467–478 (2015). https://doi.org/10.1007/s00262-015-1658-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-015-1658-8